통신신호처리를 위한 Jacket 행렬의 특성(特性)

이문호,김정수 한국인터넷방송통신학회 2021 한국인터넷방송통신학회 논문지 Vol.21 No.2

1893년 불란서 Hadamard가 발표한 직교 Hadamard 행렬에 대해 이문호교수는 1989년에 Center Weight Hadamard로 새롭게 정의하여 발표했고 1998년에는 Jacket 행렬을 발견했다. Jacket 행렬은 Hadamard 행렬을 일반 화한 것이다. 본 논문에서는 Symmetric Jacket 행렬을 구해 중요한 속성과 패턴을 분석하고 Jacket 행렬의 행렬식과 Eigenvalue을 얻는 방법을 제시하며 Eigen decomposition를 사용하여 이를 증명했다. 이러한 계산은 신호 처리 및 직교 코드 설계에 유용하다. 행렬의 체계를 분석하기 위해 DFT, DCT, Hadamard, Jacket 행렬로 비교해 본다. Galois Field의 대칭 행렬에서 Jacket 행렬의 element-wise inverse 관계를 수학적으로 증명하고 직교 성질 AB=I 관계를 유도했다. About the orthogonal Hadamard matrix announced by Hadamard in France in 1893, Professor Moon Ho Lee newly defined it as Center Weight Hadamard in 1989 and announced it, and discovered the Jacket matrix in 1998. The Jacket matrix is a generalization of the Hadamard matrix. In this paper, we propose a method of obtaining the Symmetric Jacket matrix, analyzing important properties and patterns, and obtaining the Jacket matrix's determinant and Eigenvalue, and proved it using Eigen decomposition. These calculations are useful for signal processing and orthogonal code design. To analyze the matrix system, compare it with DFT, DCT, Hadamard, and Jacket matrix. In the symmetric matrix of Galois Field, the element-wise inverse relationship of the Jacket matrix was mathematically proved and the orthogonal property AB=I relationship was derived.

內科領域에서의 最近動向

李文鎬 대한의학협회 1975 대한의학협회지 Vol.18 No.3

惡性高血壓

李文鎬,金柄國 최신의학사 1972 最新醫學 Vol.15 No.2

국내 호도나무 선발개체의 차대를 통한 과실특성 및 유전력

이문호,한상섭,홍성호 한국산림과학회 1997 한국임학회 정기학술발표논문집 Vol.1997 No.-

甲狀腺機能亢進症의 ^(131)I 治療

李文鎬,李弘揆 대한의학협회 1974 대한의학협회지 Vol.17 No.12

갑상선종의 치료

이문호,민병석,고창순,민병철,박용휘 대한핵의학회 1972 핵의학 분자영상 Vol.6 No.2

만성 간질환의 빈혈상

이문호,고창순,신현정,이정상 대한핵의학회 1971 핵의학 분자영상 Vol.5 No.2

The pathogenetic mechanisms of anemia in patients with chronic liver disease were observed. Seventeen patients with moderate to advanced hepatic diseass were studied by various methods. Only patients without previous blood loss were included : 14 had cirrhosis, 2 had active chronic hepatitis, and one had inferior vena cava obstruction with associated liver cirrhosis. The followings were the results : 1.The anemia based on red blood cell count, Hb., and Ht. was found in 76.5-78.6% of the patients. 2. Red cell indices indicated that normo-macrocytic and normochromic anemia was present is the majority of the patients. 3. No evidence of megaloblastic anemia was found on the basis of the morphological examinations. 4. Serum iron, TIBC, % saturation and iron content in the bone marrow indicated that iron deficiency anemia was present in about half of the patients. 5. In the view of the erythrocyte dynamics, primary increase in the red cell destruction was ascribed to the cause of the anemia. 6. Decrease in the red cell survival time was not correlated with MCV, % saturation and S.L. ratio. Also, hemoglobin level was not correlated with MCV, % saturation and T50 Cr. Therefore, multiple causes may be involved in the pathogenesis of the anemia. 7. Anemia as determined by the red cell volume was found in only 60% of the patients. It may be possible that hemodilutional anemia is present.

51Cr을 사용한 장관내 출혈량측정법

이문호 대한핵의학회 1970 핵의학 분자영상 Vol.4 No.1

주장관내의 출혈의 유무를 진단한다는 것은 임상적으로 대단히 중요하며 잠혈반응은 임상검출법의 하나로 많이 이용되고 있다. 잠혈반응에 사용되는 각종화학반응은 그 검출법이 비교적 간편하되 출혈량을 추정하는 것은 곤란하여 정성반응의 영역을 벗어나지 못하고 있다. 특히 우리나라에는 소화관내의 출혈을 야기하기 쉬운 위궤양, 십이지장궤양 내지 위암과 같은 각종 질환의 이환율이 많을 뿐만 아니라 십이지장충 감염자가 많아 출혈양의 측정은 각종질환의 치료방침내지 예후를 결정하는데 대단히 중요하다. 최근 방사성「크롬」(51Cr)으로 표식된 적혈구를 정주한 후 대변내에 배설되는 방사능을 측정하여 말초혈액단위량내의 방사능과 비교하여 소화관내의 출혈양을 측정하는 연구가 보고되고 있다. 저자는 출혈양이 적혈구수명측정에 미치는 영향을 관찰하는 예비실험의 하나로 종래 51Cr를 사용한 소화관내의 출혈양측정법에 대한 몇가지 기초적 연구를 시도하여 51Cr법의 신빙성여하를 검토한 바 있어 이에 보고하는 바이다. 1) Sixteen normal healthy subjects free from occult blood in the stool were selected and administered with their 51Cr labeled own blood via duodenal tube and the recovery rate of radioactivity in feces and urine was measured. The average fecal recovery rate was 90.7 percent (85.7∼97.7%) of the administered radioactivity, and the average urinary excretion rate was 0.8 percent (0.5∼1.5%). 2) There was a close correlation between the amount of blood administered and the recovery rate from the feces; the more the blood administered, the higher the recovery rate was. It was also found that the administration of the tagged blood in the amount exceeding 15ml was suitable for measuring the radioactivity in the stools. 3) In five normal healthy subject, whose circulating erythrocytes had been tagged with (51)^Cr, there was little fecal excretion of radioactivity (average 0.9 ml of blood per day). This excretion is not related to hemorrhage and the main route of excretion of such an negligible radioactivity was postulat as gastric juice and bile. 4) A comparison of the radioactivity in the blood and feces of the patients with 51Cr labeled erythrocytes seems to be a valid way of estimating intestinal blood loss.

방사성면역측정법에 의한 갑상선 자가항체 측정의 기본적 및 임상적 검토

이문호,조보연,이홍규,고창순,이명식,정재훈,민헌기 대한핵의학회 1987 핵의학 분자영상 Vol.21 No.2

To evaluate the values of the thyroid autoantibody measured by radioimmunoassay (RIA) and compare it with hemagglutination method (HA) in the normal and the thyroid disease, data were obtained from total 61B persons; 236 healthy persons, 217 patients with Graves disease (including 113 patients with undertreated Graves disease'), 100 Hashimotos disease, 31 thyroid nodule, and 34 simple goiter. RSR kit made in England was used and could be detected t:o at least 3 U/ml. The positive rates of normal group were antirnicrosomal antibody (AMA) 31.8%, antithyroglobulin antibody (ATA) 44.5% by RIA and there was no considerable change in sex and age distribution. 1n Graves disease, the positive rates of AMA and ATA were 90.4, 76.9% by RIA, 85, 39% by HA. In Hashimotos disease, 94,91% by RIA, and 87,48% by HA, respectively. The autoantibody titer by RIA in thyroid autoimmune disease as welt as in normal group was more senisit.ive than that by HA, especially in ATA. There were linear relationships between the titer of RIA and that of HA in AMA of Graves disease and AMA and ATA of Hashimotos disease. There was no relationship among thyroid autoantibody, free T, index, TBII, and TSH. The titers of AMA and ATA were found to decrease in patients with Graves disease during the course of antithyroid drug therapv. Of the 236 normal subjects, thirty-seven (15.7%) had concentrations of above 7.5 U/ml in AMA, forty-four (18. 6%) above 9 U/ml in ATA. These values were considered as the upper limit for the normal range. In Graves disease, 82,7, 53.8% were above 7.5, 9 U/ml, respectively;1n Hashimoto's disease, HZ, 79% were positive. We conclude that RIA was more sensitve than HA in measuring the thyoird autoantibody, but we will study further more for determining the normal range and its interpretation.

갑상선암의 임상적 관찰 (제3보)

이문호,이명철,김용일,최창운,박성회,최국진,조보연,문대혁,고창순,오승근 대한핵의학회 1986 핵의학 분자영상 Vol.20 No.1

Clinical features of 406 patients with histologically verified thyroid carcinomas were investigated from May, 1978 to April, 1985 at the Seoul National University Hospital with the following results. 1) The incidence of thyroid cancer according to their histological classification was 79. 8% of papillary carcinoma, 14.5% of follicular carcinoma, 1.5% of medullary carcinoma, 2.2% of anaplastic carcinoma, 2 cases of squamous carcinoma and 3 cases of lymphoma. 2) The age distribution showed the peak incidence in the fourth decade (25.1%), followed by the fifth and the third decade. 3) The ratio of male to female patients was 1:6.1. The ratio is 1:5.9 in papillary carcinoma and 1:8.8 in follicular carcinoma. 4) The mean age was 40.2 year in papillary carcinoma, 37.4 year in follicular carcinoma, 36.5 year in medullary carcinoma, 60.3 year in anaplastic carcinoma, 62.0 year in squamous carcinoma, 59.7 year in lymphoma. 5) The diameter of the thyroid masses was smaller than 1.5cm in 19.9% of the patients, from 1.5cm to 5cm in 50.5%, from 5cm to 10cm in 25.4% and larger than 10cm in 25.4%. 6) Metastasis to the regional lymph nodes at diagnosis was noted in 44.2% of total pa tients, and distant metastasis was 5%, and local infiltration was 44.2%. 7) The clinical staging was revealed 42.1% of the patients in stage Ⅰ, 9.1% in stage Ⅱ, 35.7% in stage Ⅲ, 5.2% in stage Ⅳ, and 7.9% in undetermined stage.